Table 1.
Patient and Treatment Characteristics
| No. of Patients (%) | ||||
|---|---|---|---|---|
| Characteristics | All Patients (N = 113) | All Discontinued (n = 30) | Early Discontinuation (n = 16) | Late Discontinuation (n = 14) |
| Median age, range (y) | 67 (49–86) | 69 (54–86) | 68 (54–86) | 69 (56–74) |
| Sex | ||||
| Female | 46 (41) | 15 (50) | 10 (62) | 5 (36) |
| Male | 67 (59) | 15 (50) | 6 (38) | 9 (64) |
| Smoking history | ||||
| Ever | 107 (95) | 27 (90) | 14 (88) | 13 (92) |
| Never | 6 (5) | 3 (10) | 2 (12) | 1 (7) |
| Performance status | ||||
| ECOG 0 | 61 (54) | 14 (47) | 7 (44) | 7 (50) |
| ECOG 1 | 52 (46) | 16 (53) | 9 (56) | 7 (50) |
| Tumor Histology | ||||
| Adenocarcinoma | 69 (61) | 21 (70) | 12 (75) | 9 (64) |
| Squamous cell | 34 (30) | 6 (10) | 1 (6) | 5 (36) |
| Other | 10 (9) | 3 (20) | 3 (19) | — |
| PD-L1 expression | ||||
| <1% | 29 (26) | 9 (30) | 6 (37) | 3 (21) |
| ≥1% | 55 (48) | 15 (50) | 8 (50) | 7 (50) |
| Unknown | 29 (26) | 6 (20) | 2 (13) | 4 (29) |
| AJCC eighth overall stage | ||||
| IIIA | 36 (32) | 11 (37) | 6 (38) | 5 (36) |
| IIIB | 59 (52) | 12 (40) | 7 (44) | 5 (36) |
| IIIC | 18 (16) | 7 (23) | 3 (19) | 4 (28) |
| T stage | ||||
| T0 or T1 | 31 (27) | 9 (29) | 7 (44) | 2 (14) |
| T2 | 22 (20) | 5 (17) | 4 (25) | 1 (7) |
| T3 | 29 (26) | 11 (37) | 5 (31) | 6 (43) |
| T4 | 31 (27) | 5 (17) | — | 5 (36) |
| N stage | ||||
| N0/N1 | 9 (7) | 2 (7) | — | 2 (14) |
| N2 | 62 (55) | 17 (57) | 9 (56) | 8 (57) |
| N3 | 42 (38) | 11 (37) | 7 (44) | 4 (29) |
| Median radiation dose, range (Gy) | 60 (54–70) | 60 (60–70) | 60 (60–60) | 60 (60–70) |
| Chemotherapy | ||||
| Carboplatin/paclitaxel | 48 (42) | 13 (43) | 7 (44) | 6 (43) |
| Carboplatin/pemetrexed | 31(27) | 8 (27) | 6 (37) | 2 (15) |
| Cisplatin/pemetrexed | 22 (20) | 5 (17) | 2 (13) | 3 (21) |
| Cisplatin/etoposide | 12 (11) | 4 (13) | 1 (6) | 3 (21) |
| Time to durvalumab starta | ||||
| Median, IQR (mo) | 1.5 (1.1–2) | 1.5 (0.8–1.8) | 1.5 (0.8–1.8) | 1.5 (0.8–2.1) |
| Durvalumab treatment duration | ||||
| Median, IQR (mo) | 8.5 (2.3–11.8) | 2.1 (0.9– 4.4) | 0.9 (0.5–1.8) | 4.3 (2.7–7.1) |
| Durvalumab discontinuation reason | ||||
| Radiation pneumonitis | 20 (66) | 9 (56) | 11 (79) | |
| ICI pneumonitis | 3 (10) | 2 (13) | 1 (7) | |
| Colitis | 2 (7) | 1 (6) | 1 (7) | |
| Dermatitis | 2 (7) | 2 (13) | — | |
| Myositis 3 (10) | 2 (13) | 1 (7) | ||
AJCC, American Joint Committee on Cancer; cCRT, concurrent chemoradiation; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; IQR, interquartile range; PD-L1, programmed death-ligand 1.
a
Defined from completion of cCRT.